PIVALATE ACHIEVES POSITIVE PHASE 2 DATA IN BRAIN METS TRIAL
* F-18 Pivalate PET shows high uptake regardless of origin of primary tumour * F-18 Pivalate can be used to monitor cerebral metastases * Patients without previous external beam radiation show higher tumour uptake, while those previously treated show a trend towards lower uptake MELBOURNE, A...
MD ANDERSON AND RADIOPHARM THERANOSTICS LAUNCH JOINT VENTURE TO DEVELOP NOVEL RADIOPHARMACEUTICALS
MELBOURNE, Australia, Sept. 13, 2022 /PRNewswire/ -- The University of Texas MD
Anderson Cancer Center
RADIOPHARM ENTERS INTO STRATEGIC COLLABORATION WITH LANTHEUS AND ASSUMES PD-L1 LICENSING AGREEMENT FROM NANOMAB
* Radiopharm will shortly initiate a PD-L1 Phase 1 therapeutic study in Australia in patients with NSCLC * Radiopharm acquired from NanoMab, Ltd. worldwide rights to PD-L1 technology for therapeutic use, as well as to imaging rights inChina MELBOURNE, Australia, Aug. 3, 2022 /PRNewswire/ -- R...
RAD adds brain tumor technology to portfolio
* Sublicensing of promising imaging & therapeutic radiopharmaceutical from leading US university,Case Western Reserve University (CWRU), Ohio * PTPµ (PTPmu), the target, is a unique biomarker present only in tumor cells but not healthy cells * The radionuclide carrying PTPµ-targeting agent h...
